First Quadrant’s Intersect ENT, Inc XENT Stock Holding History

First Quadrant’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20,000	Closed	-$546K	–	566
2021 Q4	$546K	Hold	20,000	–	–	0.06%	240
2021 Q3	$544K	Hold	20,000	–	–	0.06%	236
2021 Q2	$342K	Hold	20,000	–	–	0.04%	284
2021 Q1	$418K	Hold	20,000	–	–	0.04%	282
2020 Q4	$458K	Hold	20,000	–	–	0.05%	254
2020 Q3	$326K	Hold	20,000	–	–	0.04%	272
2020 Q2	$271K	Buy	+20,000	New	+$233K	0.04%	372
2019 Q1	–	Sell	-3,040	Closed	-$86K	–	850
2018 Q4	$86K	Sell	3,040 -133	-4%	-$3.9K	0.01%	666
2018 Q3	$91K	Buy	+3,173	New	+$95.3K	﹤0.01%	724

Other funds holding XENT

Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Quadrant's XENT Position: Q1 2022 in Review

First Quadrant sold out of Intersect ENT, Inc (XENT) in Q1 2022, closing a stake of 20,000 shares — an estimated $546K sold.

First Quadrant first reported a position in XENT in Q3 2018 and held it in 9 quarters. The position peaked at $546K in Q4 2021. 131 funds tracked by Wall St. Rank hold XENT as of Q1 2022.

First Quadrant reported no remaining Intersect ENT, Inc position as of Q1 2022 after selling out during the quarter.
First Quadrant sold 20,000 Intersect ENT, Inc shares in Q1 2022, an estimated $546K.
First Quadrant first reported a position in Intersect ENT, Inc in Q3 2018 and held it in 9 quarters.
First Quadrant's Intersect ENT, Inc position peaked at $546K in Q4 2021.
131 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q1 2022.

Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.